This is therefore a contrasting of the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation in Cerecor Inc. (NASDAQ:CERC) and Coherus BioSciences Inc. (NASDAQ:CHRS). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cerecor Inc. 18.33M 11.68 41.71M -1.05 0.00
Coherus BioSciences Inc. N/A 0.00 209.34M -3.13 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Cerecor Inc. and Coherus BioSciences Inc.

Profitability

Table 2 shows the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Cerecor Inc. -227.55% -164.9% -63.2%
Coherus BioSciences Inc. 0.00% -742.4% -126.3%

Liquidity

The Current Ratio and Quick Ratio of Cerecor Inc. are 0.7 and 0.7 respectively. Its competitor Coherus BioSciences Inc.’s Current Ratio is 5.3 and its Quick Ratio is 5.3. Coherus BioSciences Inc. can pay off short and long-term obligations better than Cerecor Inc.

Analyst Recommendations

Cerecor Inc. and Coherus BioSciences Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cerecor Inc. 0 0 2 3.00
Coherus BioSciences Inc. 0 0 2 3.00

Cerecor Inc. has a 109.16% upside potential and an average price target of $10.5. Coherus BioSciences Inc. on the other hand boasts of a $25 average price target and a 43.10% potential upside. Based on the analysts belief we can conclude, Cerecor Inc. is looking more favorable than Coherus BioSciences Inc.

Institutional & Insider Ownership

Institutional investors owned 52.6% of Cerecor Inc. shares and 98.8% of Coherus BioSciences Inc. shares. Insiders owned 4% of Cerecor Inc. shares. Comparatively, 0.4% are Coherus BioSciences Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cerecor Inc. 12.71% 31.35% 92.94% 36.6% 54.52% 111.46%
Coherus BioSciences Inc. 1.49% 11.66% 36.64% -25.41% 53.37% 66.08%

For the past year Cerecor Inc. has stronger performance than Coherus BioSciences Inc.

Summary

Cerecor Inc. beats on 8 of the 10 factors Coherus BioSciences Inc.

Cerecor Inc., a clinical-stage biopharmaceutical company, develops drugs to treat patients with neurological and psychiatric disorders. It develops CERC-501, which has completed Phase II clinical trial for the adjunctive treatment of major depressive disorder (MDD), as well as to treat substance use disorders; CERC-301 that has completed Phase II clinical trial for the adjunctive treatment of patients with MDD; and CERC-406 that is in preclinical stage to treat residual cognitive impairment symptoms in patients with MDD. Cerecor Inc. also intends to develop CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet’s Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *